Invention in the REGENERATIVE MEDICINE is what we do every day, benefits of patients is our final goal
| Cata #: | Name of Product: | Price: |
| HRP-2020 | Recombinant Human CT89 N-terminal-11R Protein | $300 |
| Product Name: | Recombinant Human CT89 N-terminal-11R Protein |
| Catalog #: | HRP-2020 |
| Manufacture: | LD Biopharma, Inc. |
| Intruduction: | Human C-Jun-amino-terminal kinase-interacting protein 4 (SPAG9, also named as CT89) encodes 1321aa protein. The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Isoform 5 may play a role in spermatozoa-egg-interaction. Normally, this gene expression is restricted in human testis tissue, but it also expressed in a wide variety of cancer tissues. As such, CT89 is a good candidate protein for anti-tumor vaccine development. N-terminal domain of human CT89 cDNA (2 - 638aa, derived from BC146755) was constructed with codon optimization gene synthesis and expressed with a human Alpha Fetal protein at N-terminal and 11 arginine (11R tag) at C-terminal. This protein was expressed in E. coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified. |
| Gene Symbol: | CT89 (SPAG9: HSS; KIAA0516; MAPK8IP4; SYD1) |
| Accession Number: | NP_001124000 |
| Species: | Human |
| Package Size: | 50 µg / Vial |
| Composition: | 0.5 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT. |
| Storage: | In Liquid. Keep at -80°C for long term storage. Product is stable at 4 °C for at least 30 days. |
| Key Reference: | Ren B, et al., Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer. Oncol. Rep. 35 (5), 2599-2605 (2016) Wang X, et al., MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. Biochem. Biophys. Res. Commun. 470 (3), 620-626 (2016) Zhang,L., et al., SPAG9 promotes endometrial carcinoma cell invasion through regulation of genes related to the epithelial-mesenchymal transition. Eur. J. Gynaecol. Oncol. 37 (3), 312-319 (2016) Salmaninejad A, et al. Cancer/Testis Antigens: Expression, regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunol Invest. Oct; 45(7): 619-640. (2016). Nicole Brooks, et al. Comparative Immunogenicity of a Cytotoxic T cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides. Molecules. 20, 14033-14050. (2015) Madiha Derouazi, et al. Novel cell penetration peptide based vaccine induces robust CD4+ and CD8+ T cell mediated antitumor immunity. Cancer Res; 75(15) August 1, 3020-3031 (2015) |
| Applications: | 1. May be used for in vitro CT89 mediated anti-tumor immunotherapy for T cell activation study with this fusion protein for intracellular delivery in MHC-II pathway. 2. As immunogen for specific antibody production. |
| Quality Control: | Purity: > 80% by SDS-PAGE. |
| Recombinant Protein Sequence: | MTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSGGSHHHHHHGSENLYFQ/GELEDGVVYQEEPGGSGAVMSERVSGLAGSIYREFERLIGRYDEEVVKELMPLVVAVLENLDSVFAQDQEHQVELELLRDDNEQLITQYEREKALRKHAEEKFIEFEDSQEQEKKDLQTRVESLESQTRQLELKAKNYADQISRLEEREAELKKEYNALHQRHTEMIHNYMEHLERTKLHQLSGSDQLESTAHSRIRKERPISLGIFPLPAGDGLLTPDAQKGGETPGSEQWKFQELSQPRSHTSLKVSNSPEPQKAVEQEDELSDVSQGGSKATTPASTANSDVATIPTDTPLKEENEGFVKVTDAPNKSEISKHIEVQVAQETRNVSTGSAENEEKSEVQAIIESTPELDMDKDLSGYKGSSTPTKGIENKAFDRNTESLFEELSSAGSGLIGDVDEGADLLGMGREVENLILENTQLLETKNALNIVKNDLIAKVDELTCEKDVLQGELEAVKQAKLKLEEKNRELEEELRKARAEAEDARQKAKDDDDSDIPTAQRKRFTRVEMARVLMERNQYKERLMELQEAVRWTEMIRASRENPAMQEKKRSSIWQFFSRLFSSSSNTTKKPEPPVNLKYNAPTSHVTPSVKKRSSTLSQLPGDKSKAFDFLSEETEASLASRREQKREQYRQVKAHVQKESGGGGSPGRRRRRRRRRRR Download Datasheet |